33rd week of 2012 patent applcation highlights part 45 |
Patent application number | Title | Published |
20120208709 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE - The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease, MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers. | 2012-08-16 |
20120208710 | Noninvasive Diagnosis of Fetal Aneuoploidy by Sequencing - Disclosed is a method to achieve digital quantification of DNA (i.e., counting differences between identical sequences) using direct shotgun sequencing followed by mapping to the chromosome of origin and enumeration of fragments per chromosome. The preferred method uses massively parallel sequencing, which can produce tens of millions of short sequence tags in a single run and enabling a sampling that can be statistically evaluated. By counting the number of sequence tags mapped to a predefined window in each chromosome, the over- or under-representation of any chromosome in maternal plasma DNA contributed by an aneuploid fetus can be detected. This method does not require the differentiation of fetal versus maternal DNA. The median count of autosomal values is used as a normalization constant to account for differences in total number of sequence tags is used for comparison between samples and between chromosomes. | 2012-08-16 |
20120208711 | Method for Analysis of DNA Methylation Profiles of Cell-Free Circulating DNA in Bodily Fluids - The invention can be summarized as follows. There is provided a method for analyzing DNA methylation profiles of cell-free DNA in body fluids by enriching a methylated or unmethylated fraction of DNA from cell-free DNA and subjecting the enriched DNA to microarray based methylome profiling and bioinformatics data analysis. | 2012-08-16 |
20120208712 | SIRTUIN 5 POLYMORPHISMS AND NEUROLOGICAL DISEASES - A method for determining a subject's risk of developing a neurological disease or disorder such as Huntington's or Parkinson's disease, based on the presence of SIRT5 | 2012-08-16 |
20120208713 | METHODS AND COMPOSITIONS RELATING TO FUSIONS OF ALK FOR DIAGNOSING AND TREATING CANCER - Disclosed are methods and compositions for detecting the presence of a cancer in a subject and assessing the efficacy of treatments for the same. The disclosed method use reverse transcription polymerase chain reaction (RT-PCR) and multiplex polymerase chain reaction techniques as well as Template Exchange Extension Reaction (TEER) to detect the presence of point mutations, truncations, or fusions of anaplastic lymphoma kinase. | 2012-08-16 |
20120208714 | DNA-BASED METHODS FOR CLONE-SPECIFIC IDENTIFICATION OF STAPHYLOCOCCUS AUREUS - MRSA CC398 is a clone of | 2012-08-16 |
20120208715 | METHODS AND COMPOSITIONS FOR DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION (AMI) - Embodiments of the invention utilizes advanced detection methodologies, such as the lab-on-a-chip (LOC) technology, as a cost-effective, efficient, ultra-sensitive rapid method for diagnosing Acute Myocardial Infarction (AMI) in human subjects. In certain aspects, multiple biomarkers of AMI are concurrently detected and measured in serum and saliva to provide a more efficient, sensitive and accurate diagnosis of AMI. | 2012-08-16 |
20120208716 | DEVICE AND METHOD FOR PARTICLE COMPLEX HANDLING - An embodiment of the invention relates to a device for detecting an analyte in a sample. The device comprises a fluidic network and an integrated circuitry component. The fluidic network comprises a sample zone, a cleaning zone and a detection zone. The fluidic network contains a magnetic particle and/or a signal particle. A sample containing an analyte is introduced, and the analyte interacts with the magnetic particle and/or the signal particle through affinity agents. A microcoil array or a mechanically movable permanent magnet is functionally coupled to the fluidic network, which are activatable to generate a magnetic field within a portion of the fluidic network, and move the magnetic particle from the sample zone to the detection zone. A detection element is present which detects optical or electrical signals from the signal particle, thus indicating the presence of the analyte. | 2012-08-16 |
20120208717 | Systems and methods for characterizing kidney diseases - The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders. | 2012-08-16 |
20120208718 | SCHIZOPHRENIA TREATMENT RESPONSE BIOMARKERS - The present invention provides biomarker of antipsychotic treatment response in patients with schizophrenia and other disorders involving DRD2 and methods for using the same. | 2012-08-16 |
20120208719 | ASSESSING RHEUMATOID ARTHRITIS - This document provides methods and materials related to assessing mammals (e.g., humans) with arthritis (e.g., RA). For example, methods and materials for using cytokine response profiles to assist clinicians in assessing RA disease activity, assessing the likelihood of response and outcomes of RA therapy, predicting long-term RA disease outcomes, and assessing the risk of developing heart conditions are provided. Methods and materials for using cytokine response profiles to assist clinicians in diagnosing arthritis (e.g., RA) also are provided. | 2012-08-16 |
20120208720 | RAPID DISPLAY METHOD IN TRANSLATIONAL SYNTHESIS OF PEPTIDE - Provided are linkers suitable for preparing a conjugate of a nucleic acid and a peptide as a translation product thereof in a reconstituted cell-free translation system in genotype-phenotype mapping (display methods), said linkers comprising a single-stranded structure region having a side chain base pairing with the base at the 3′-end of an mRNA at one end and a peptidyl acceptor region containing an amino acid attached to an oligo RNA consisting of a nucleotide sequence of ACCA via an ester bond at the other end, characterized in that the ester bond is formed by using an artificial RNA catalyst. Also provided are display methods using [mRNA]-[linker]-[peptide] conjugates assembled via such linkers. | 2012-08-16 |
20120208721 | NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID RECEPTORS ANTIBODIES AND USES THEREOF - The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively. | 2012-08-16 |
20120208722 | SURFACE ENHANCED RAMAN SPECTROSCOPY PLATFORMS AND METHODS - Surface enhanced Raman spectroscopy (SERS) platforms and methods of making and using such platforms are disclosed herein. Such platforms can be made by immobilizing a biomaterial (e.g., a carbohydrate such as a glycan) by reacting an azide-functional group attached to a surface of a solid substrate with at least one cyclooctyne (e.g., a dibenzocyclooctyne) having a biomaterial or biomaterial binding group attached thereto. In certain embodiments the immobilized biomaterial can be detected using, for example, surface enhanced Raman spectroscopy. | 2012-08-16 |
20120208723 | OLIGOMER PROBE ARRAY WITH IMPROVED SIGNAL-TO-NOISE RATIO AND DETECTION SENSITIVITY AND METHOD OF MANUFACTURING THE SAME - An oligomer probe array with improved signal-to-noise ratio and desired detection sensitivity even when a reduced design rule is employed includes a substrate, a plurality of probe cell active regions formed on or in the substrate, each of the plurality of probe cell active regions having a three-dimensional surface and being coupled with at least one oligomer probe with its own sequence, and a probe cell isolation region defining the probe cell active regions and having no functional groups for coupling with the oligomer probes on a surface. | 2012-08-16 |
20120208724 | LINKING SEQUENCE READS USING PAIRED CODE TAGS - Artificial transposon sequences having code tags and target nucleic acids containing such sequences. Methods for making artificial transposons and for using their properties to analyze target nucleic acids. | 2012-08-16 |
20120208725 | Drilling Fluid Additive and Method for Improving Lubricity or Increasing Rate of Penetration in a Drilling Operation - The present invention relates to a drilling fluid additive for improving lubricity or rate of penetration (ROP) in a drilling operation, such as an oil and gas drilling operation. The additive comprises particles of wax or waxy substance, or a mixture of two or more types of the particles having distinct properties, such as particle size, type of wax or waxy substance, melt point, solubility, dissolution rate, hardness, shape, blocking ability, or a combination thereof. In certain embodiments, the additive is environmentally friendly and biodegradable. The invention also relates to a drilling fluid comprising the drilling fluid additive of the invention. A method of improving lubricity or increasing ROP in a drilling operation is also provided, as well as a use of particles of wax or waxy substance or mixture thereof as a drilling fluid additive for improving lubricity or increasing ROP in a drilling operation. | 2012-08-16 |
20120208726 | COMPOSITION AND METHOD FOR REMOVING FILTER CAKE - An embodiment of the present disclosure is directed to a well servicing fluid emulsion. The well servicing fluid is formulated with components comprising an ester of an organic acid for which the pK | 2012-08-16 |
20120208727 | High Temperature Fracturing Fluids and Methods - Subterranean treatment fluids comprising: an aqueous base fluid and a reaction product of a gelling agent comprising a copolymer or salt thereof comprising N-[tris(hydroxymethyl)methyl]acrylamide, 2-acrylamido-2-methylpropanesulfonic acid or a salt thereof, acrylamide; and a crosslinking agent. Such treatment fluids are particularly well-suited for high temperature applications. In particular, they are suited for subterranean temperatures up to about 400° F. | 2012-08-16 |
20120208728 | WELL TREATMENT - The present invention provides a method for inhibiting scale formation within a hydrocarbon producing system (e.g. a subterranean formation), said method comprising contacting said system with a clay mineral, an organosilane and a scale inhibitor. | 2012-08-16 |
20120208729 | Polymeric Acid Precursor Compositions And Methods - A composition is formed from a polymeric acid precursor, such as polylactic acid (PLA), that is a least partially dissolved within a polymer dispersing solvent. An emulsion may be from polymeric acid precursor that is at least partially dissolved within a solvent and a liquid that is substantially immiscible with the solvent. In certain cases, the molecular weight of the polymeric acid precursor may be reduced in forming the solution. The solution may be used in treating a formation penetrated by a wellbore. | 2012-08-16 |
20120208730 | Friction and Wear Modifiers Using Solvent Partitioning of Hydrophilic Surface-Interactive Chemicals Contained in Boundary Layer-Targeted Emulsions - A wear and/or friction reducing additive for a lubricating fluid in which the additive is a combination of a moderately hydrophilic single-phase compound and an anti-wear and/or anti-friction aqueous salt solution. The aqueous salt solution produces a coating on boundary layer surfaces. The lubricating fluid can be an emulsion-free hydrophobic oil, hydraulic fluid, antifreeze, or water. Preferably, the moderately hydrophilic single-phase compound is sulfonated castor oil and the aqueous salt solution additionally contains boric acid and zinc oxide. The emulsions produced by the aqueous salt solutions, the moderately hydrophilic single-phase compounds, or the combination thereof provide targeted boundary layer organizers that significantly enhance the anti-wear and/or anti-friction properties of the base lubricant by decreasing wear and/or friction of sliding and/or rolling surfaces at boundary layers. | 2012-08-16 |
20120208731 | Lubricating Composition Containing an Ester - The invention relates to a method of lubricating a limited slip differential comprising supplying to the limited slip differential a lubricating composition containing (a) an oil of lubricating viscosity, and (b) a C4-30-diester of a dicarboxylic acid. The invention further provides for the use of the C4-30-diester of a dicarboxylic acid as a friction modifier, typically in a limited slip differential. | 2012-08-16 |
20120208732 | ESTERS FOR USE AS A BASE STOCK AND IN LUBRICANT APPLICATIONS - This invention relates to base ester compounds and complex ester compounds that can be used as a base stock for lubricant applications or a base stock blend component for use in a finished lubricant or for particular applications, and methods of making the same. The base ester compounds and complex esters described herein comprise dimer and/or trimer esters, and their respective branched derivatives. | 2012-08-16 |
20120208733 | Soap Scum Indicating Cleaning Composition - Soap scum indicating cleaning compositions are described. In one case, the soap scum indicating cleaning composition includes a cleaning component configured to clean a surface. The soap scum indicating cleaning composition also includes a visual indicator component configured to distinguish areas of the surface that have soap scum from different areas of the surface that have little or no soap scum. | 2012-08-16 |
20120208734 | LIQUID DISHWASHER DETERGENT - The invention relates to dishwasher detergents, comprising a packaging means and two liquid washing or cleaning agents A and B, which are present in said packaging means separate from each other and which have the following composition: A: −10 to 55 wt. % builder(s); −0.1 to 15 wt. % enzyme(s); −0.001 to 30 wt. % bleach activator; −20 to 70 wt. % water; and B: −50 to 99.9 wt. % water; −0.1 to 50 wt. % oxygen bleaching agent, −<20 wt. % further ingredients, characterized in that the liquid cleaning agents A and B have a pH value (20° C.) of less than 9. The dishwasher detergents are characterized by good cleaning power when dishes are washed in the dishwasher. | 2012-08-16 |
20120208735 | Hydrophobic and Particulate Soil Removal Composition - The invention relates to a hydrophobic and particulate soil removal composition and method for removal of hydrophobic and particulate soil from an article. Stubborn hydrophobic greasy or oily soils, including associated organic particulate soils, such as finely divided elemental carbon, are frequently encountered on hard surfaces including vehicle parts. The composition is selected to provide enhanced soil removal, preferably in vehicle cleaning applications. | 2012-08-16 |
20120208736 | Treatment of Hard Surfaces - Hard surfaces can be treated to improve soil resistance, particularly resistance to oily soils, by applying a composition of a quaternised, polyamine, polypropoxylate, polyethoxylate. The polyamine can be a polyethyleneimme, desirably having a molecular weight of from 10 to 50 kDa. The average length of the polypropylenoxy chains is desirably from 10 to 100 and the polyethylenoxy chains from 5 to 50 (each per NH group in the polyamine), particularly at a molar ratio of PO:EO of about 3:1. The degree of quaternisation of the nitrogen atoms in the polyamine is desirably from 70 to 100%. The polymer will usually be used in solution in water or an aqueous formulation, which may include detergent and other detergent formulation components. | 2012-08-16 |
20120208737 | Liquid Detergent Composition Comprising an External Structuring System Comprising a Bacterial Cellulose Network - A structured liquid detergent composition in the form of a liquid matrix made up of an external structuring system of a bacterial cellulose network; water; and surfactant system including an anionic surfactant; a nonionic surfactant; a cationic surfactant; an ampholytic surfactant; a zwitterionic surfactant; or mixtures thereof, wherein said liquid matrix has a yield stress of from about 0.003 Pa to about 5.0 Pa at about 25° C. and provides suitable particle suspension capabilities and shear thinning characteristics. | 2012-08-16 |
20120208738 | NONIONIC SURFACTANT AND SURFACTANT COMPOSITION COMPRISING THE SAME - The present invention provides the nonionic surfactant represented by the formula (1): | 2012-08-16 |
20120208739 | LIQUID CLEANING COMPOSITIONS - Liquid cleaning compositions are described herein that include a metal bleach catalyst which is a complex of a transition-metal and a macrocyclic ligand, the ligand having a calculated Octanol/Water Partition Coefficient value of from about −1.50 to about −0.10, a formulation enabling fraction comprising at least one formulation enabling ingredient, the formulation enabling fraction having a Hydrophilic Index of from about 4.0 to about 10.0, and a formulation deactivating fraction comprising at least one formulation deactivating ingredient that has a calculated Octanol/Water Partition Coefficient value of from about −3.5 to about −0.10. | 2012-08-16 |
20120208740 | METHOD FOR PREPARING A SOLID FORM OF ACETIC ACID AND PRODUCTS THEREOF - The present invention discloses a method of preparing a solid form of acetic acid. The method at least includes the steps of combining a solid acid and a metal acetate with a solvent to form a slurry. After a predetermined period of time, a solid form of acetic acid is recovered. The present invention also includes a solid product of acetic acid produced by the above-mentioned method. There is also disclosed a formulation including the solid product of acetic acid according to the present invention. Further, there is disclosed a cleaning system including the formulation according to the present invention. | 2012-08-16 |
20120208741 | ODORANTS WITH ANISIC NOTES - The present invention concerns the use as perfuming ingredients of para-substituted derivatives of α-methyl cinnamic alcohol of formula (I) in the form of any one of its stereoisomers or a mixture thereof, and wherein R represents a hydrogen atom, a C | 2012-08-16 |
20120208742 | Compositions of a peptide targeting system for treating cancer - This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells. | 2012-08-16 |
20120208743 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES - The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis). | 2012-08-16 |
20120208744 | ANTI-MICROBIAL AGENTS AND COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF - Anti-microbial compositions for inhibiting gram-negative bacterial growth include inhibitors of one or more interactions between the bacterial proteins TonB and ExbD and/or between the bacterial proteins TolR and TolA. Methods of producing and using the anti-microbial compositions (e.g., treating gram-negative bacterial infections in a mammalian subject) are described. Novel antibiotics that target the TonB system and prevent bacterial growth are described herein. | 2012-08-16 |
20120208745 | TREATMENT OF HIV - We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments. | 2012-08-16 |
20120208746 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CYCLOPHILIN-BINDING COMPOUNDS - Methods of predicting the response in a patient infected with hepatitis C virus (HCV) to a treatment regime involving the use of a cyclophilin-binding compound are described which provide for improvements in treatments, pharmaceutical compositions, dosing regimen, assays, kits, and other aspects of the art. | 2012-08-16 |
20120208747 | NOVEL PEPTIDE FOR AUGMENTING AND EXPRESSION OF BDNF AND PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE OR PARKINSON'S DISEASE, COMPRISING THE SAME - Disclosed are peptides for augmenting the expression of BDNF (brain-derived neurotrophic factor) and a pharmaceutical composition for the prevention and treatment of Alzheimer's disease or Parkinson's disease, comprising the same. The peptides can induce the expression of BDNF in dopamine-reactive human cells, pass easily through the blood-brain barrier thanks to their low molecular weights and are almost free of cytotoxicity. Thus, they are useful in the prevention and treatment of neuropathies such as Alzheimer's disease or Parkinson's disease. | 2012-08-16 |
20120208748 | PEPTIDE COMPOSITIONS AND METHODS FOR TREATING PATIENTS - The present invention is directed to peptide compositions and methods of using the peptide compositions to treat prediabetes, diabetes, obesity, high blood pressure and metabolic syndrome. | 2012-08-16 |
20120208749 | Insulin derivatives - The present invention is related to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of B chain or to an ε-amino group of a Lys residue present in the B chain of the parent insulin molecule via an amide bond which side chain comprises one or more residues of ethyleneglycol, propyleneglycol and/or butyleneglycol containing independently at each termini a group selected from —NH | 2012-08-16 |
20120208750 | USE OF PROTEIN KINASE C DELTA (PKCD) INHIBITORS TO TREAT DIABETES, OBESITY, AND HEPATIC STEATOSIS - Described are methods of improving insulin sensitivity, and treating fatty liver disease (including non-alcoholic steatohepatitis (NASH)), by administering specific inhibitors of PKC delta. | 2012-08-16 |
20120208751 | Methods for Regulating Neurotransmitter Systems by Inducing Counteradaptations - The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to period between administrations of no greater than 1/2. The methods of the present invention may be used to address a whole host of undesirable mental, neurological and physiological conditions. | 2012-08-16 |
20120208752 | CELL PROLIFERATION-PROMOTING PEPTIDE AND USE THEREOF - A cell proliferation promoter includes, as an active ingredient, an artificially synthesized peptide that includes (A) an amino acid sequence constituting a membrane-permeable peptide and (B) an amino acid sequence selected from SEQ ID NOs: 19 to 103 or an amino acid sequence formed by substituting, deleting and/or adding one or several amino acid residues in the selected amino acid sequence. | 2012-08-16 |
20120208753 | Composition and Method for the Treatment or Prevention of Spinal Disorders III - The present invention relates to compositions comprising a modulator of GDF-6 signaling for the prevention of and/or treatment of a spinal disorder and/or spinal pain, eg., caused by and/or associated with intervertebral disc degeneration and methods of treatment of a spinal disorder and/or spinal pain comprising administering a modulator of GDF-6 signaling, or a composition comprising thereof. | 2012-08-16 |
20120208754 | STABLE NON-AQUEOUS SINGLE PHASE VISCOUS VEHICLES AND FORMULATIONS UTILIZING SUCH VEHICLES - This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10 | 2012-08-16 |
20120208755 | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers - The use of GLP-1 receptor agonists, such as glucagon-like peptide-1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered. | 2012-08-16 |
20120208756 | COMPOSITION FOR EXTERNAL PREPARATION FOR SKIN - The problem to be solved by the present invention is to provide a safe and efficacious therapeutic agent for dermatitis which is not only safe and efficacious for patients with dermatitis, in particular atopic dermatitis, but also significantly effective for severe cases that are judged to be intractable by conventional external preparations, and which is also safely applicable to affected areas such as the face and neck, as well as to subjects with sensitive skin, such as infants and females. Furthermore, the invention aims to provide an external preparation that is efficacious as skin care cosmetics having effects to improve elasticity and wrinkles of the skin, moisturizing effects, and hair-growth effects. | 2012-08-16 |
20120208757 | USE OF HYALURONAN FOR PROMOTING ANGIOGENESIS - Use of hyaluronan, either alone or in combination with collagen, for promoting angiogenesis. | 2012-08-16 |
20120208758 | COMPOSITION FOR THE ATTACHMENT OF IMPLANTS TO COLLAGEN OR OTHER COMPONENTS OF BIOLOGICAL TISSUE - The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological tissue, allowing the implant to be bound to the biological tissue in a short period of time after implantation. The invention also relates to the use and manufacture of this novel composition, as well as a novel use for the protein CNA. | 2012-08-16 |
20120208759 | LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAME - Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed. | 2012-08-16 |
20120208760 | THROMBOPOIETIC COMPOUNDS - The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal. | 2012-08-16 |
20120208761 | TYPE I-TYPE IV COLLAGEN HYBRID GEL - It is an object of the present invention to provide a Type I-Type IV collagen hybrid gel, which maintains characteristics of a Type IV collagen and is superior in gel strength. It is the Type I-Type IV collagen hybrid gel obtained by mixing 100 to 500 parts by mass of the Type I collagen having fibrosis ability, relative to 100 parts by mass of the Type IV collagen having gelling ability. A three-dimensional structure is formed, where a membrane-like substance by the Type IV collagen is formed onto a fibrous substance by the Type I collagen, so as to be able to provide cell culture environment approximate to a basement membrane of a living body. | 2012-08-16 |
20120208762 | Methods of Diagnosing Diastolic Dysfunction - Diagnostic methods relating to a cardiac ventricular dysfunction are provided. In some embodiments, the diagnostic method is a method of diagnosing diastolic dysfunction in the absence of systolic dysfunction in a subject. The method comprises assaying a sample obtained from the subject for evidence of activation of renin-angiontensin system (RAS), evidence of oxidative stress, a level of adiponectin, or a combination thereof, wherein, when there is a lack of evidence of RAS activation, a lack of evidence of oxidative stress, a reduction in the level of adiponectin, or a combination thereof, as compared to a control subject, the subject is diagnosed with diastolic dysfunction in the absence of systolic dysfunction. A method of diagnosing a type of cardiac ventricular dysfunction, a method of determining a therapeutic regimen for a subject suffering from a cardiac ventricular dysfunction and methods of treating diastolic dysfunction in the absence of systolic dysfunction are also provided. | 2012-08-16 |
20120208763 | NAP ALPHA-AMINOISOBUTYRIC ACID ANALOG WITH NEUROPROTECTIVE ACTIVITY - The invention relates to compositions and methods to confer protection on neurons. Peptides derived from the NAPVSIPQ (SEQ ID NO:4) peptide and including branched amino acids, such as alpha-aminoisobutyric acid, are included. Also included are methods of preventing and treating neurodegenerative disorders and damage caused by neurotoxic substances. | 2012-08-16 |
20120208764 | METHOD AND COMPOSITIONS FOR TREATING STROKE WITH FEVER - The invention provides methods of treating stroke and related conditions exacerbated by fever and/or hyperglycemia by administering peptides or peptidomimetics that inhibit binding of NMDAR 2B to PSD-95 to a patient. | 2012-08-16 |
20120208765 | MODIFIED AGRIN-FRAGMENT CAPABLE OF RESTORING MUSCLE STRENGTH FOR USE AS A MEDICAMENT - Modified agrin fragment having in vivo activity, comprising at least the domains LG2 and LG3 of human agrin in covalently interlinked form and modified in such a way that the fragment cannot be cleaved by neurotrypsin for use as medicament. | 2012-08-16 |
20120208766 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg, alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist. | 2012-08-16 |
20120208767 | Method to Detect or Treat Painful Bladder Syndrome based on Relation to Quinone Oxidoreductase 1 - A method includes obtaining a biological sample from a subject that does not display a symptom of Painful Bladder Syndrome (PBS). The method also includes analyzing the biological sample for a mutated form of NAD(P)H dehydrogenase [quinone], also known as Quinone Oxidoreductase 1, abbreviated NQO1, or a mutation of a NQO1 gene. The method also includes determining a risk of PBS for the subject based on analyzing the biological sample. In some methods, the mutation determined to present an increased risk is a cytosine to thymine nucleotide substitution at a position that leads to a proline to serine amino acid substitution at amino acid position 187 to produce a protein NQO1P187S. Another method includes selecting a subject that has above normal risk of Painful Bladder Syndrome (PBS) or is expressing a symptom of PBS, and treating the subject with a therapeutically effective amount of an antioxidant. | 2012-08-16 |
20120208768 | SPECIFIC BINDING SITES IN COLLAGEN FOR INTEGRINS AND USE THEREOF - The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods to identify specific integrin inhibitors, sequences of these inhibitors and their use in inhibiting pathophysiological conditions that may arise due to integrin-collagen interaction. | 2012-08-16 |
20120208769 | Chemokine-Mucin Fusions Linked to Glycosylphosphatidylinositol (GPI)-Anchors in Tissue Regeneration and as Tumour Immune Adjuvants - The present invention relates to chemokine-mucin fusions linked to glycosylphosphatidylinositol (GPI)-anchors and their use as anti-cancer adjuvants and as agents in tissue regeneration and suppression of vascular damage. GPI-linked chemokines are incorporated in the surface membrane of tumour cells and effect a recruitment of cytotoxic immune cells to the tumour site following injection in vivo. Leukocytes, cytotoxic T-cells and NK cells target the chemokine-GPI-anchored tumour cells and modulate cell-mediated lysis of the tumour cells. The efficiency of GPI-anchoring and modulation of immune cells can be further enhanced by linking the chemokine to a mucin domain followed by the GPI-anchor. The GPI-anchored chemokines, with or without mucin domain, are remarkably useful for the inhibition of tumour growth, tissue regeneration, and suppression of acute vascular damage to allografts. | 2012-08-16 |
20120208770 | Carcinoma Homing Peptide (CHP), Its Analogs, and Methods of Using - A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments. | 2012-08-16 |
20120208771 | SYNTHETIC CHOLESTERYLAMINE-LINKER DERIVATIVES FOR AGENT DELIVERY INTO CELLS - Synthetic cholesterylamine-linkers can include derivatives of cholesterol, cholesteryl, or sitosteryl coupled through the linker to an agent for delivery into cells. The cholesterylamines are thought to mimic cholesterol in the capacity and mechanism for enhanced entry into cells. The configuration of the cholesterylamine-linker that is thought to provide for enhanced entry into cells includes a cholesterylamine that is coupled to a linker from the amine, and which linker includes a negative charge at a spatial distance from the amine of the cholesterylamine. | 2012-08-16 |
20120208772 | CYTOKINE ZALPHA11 LIGAND - Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described. | 2012-08-16 |
20120208773 | PHARMACEUTICAL COMPOSITIONS WITH TETRABENAZINE - The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder. | 2012-08-16 |
20120208774 | METHOD FOR INHIBITING "MELANOMA INHIBITORY ACTIVITY" MIA - The present invention is directed to peptides, antibodies and antibody fragments inhibiting activity of “Melanoma Inhibitory Activity” (MIA). | 2012-08-16 |
20120208775 | Sorbitol polyesters having liquid and solid domains - The present invention is directed to a series of sorbitol esters that have two different molecular weight ester chains, one solid and one liquid, which when combined into a single molecule make a polymer that is solid, but has very unique flow properties. These materials find applications as additives to formulations in personal care products where there is a desire to have a structured film (provided by the solid fatty group) and flow properties, (provided by the liquid fatty group). These compounds by virtue of their unique structure provide outstanding skin feel. | 2012-08-16 |
20120208776 | ANTI-NEOPLASTIC COMPOSITIONS COMPRISING EXTRACTS OF BLACK COHOSH - A method is provided for treating, preventing or ameliorating neoplasia in a subject. This method includes administering to the subject an amount of actein or an amount of an extract of black cohosh that contains a triterpene glycoside, which amount of the actein or black cohosh is effective to treat, prevent or ameliorate the neoplasia, in combination with an amount of a statin which is effective to treat, prevent, or ameliorate the neoplasia. Related methods for treating, preventing or ameliorating breast cancer, or liver cell neoplasia are also provided. In addition, methods for modulating a cholesterol biosynthesis pathway and a stress response pathway in a subject are provided. These methods include administering to a subject a composition comprising an anti-neoplastic synergistic amount of a statin and actein. Compositions for carrying out such methods are also provided. | 2012-08-16 |
20120208777 | DIOSMETIN COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I): | 2012-08-16 |
20120208778 | AVERMECTINS AND MILBEMYCINS FOR THE TREATMENT, PREVENTION OR AMELIORATION OF FLAVIVIRUS INFECTIONS - Avermectin and milbemycin compounds, particularly the substance ivermectin, for preparing an antiviral medicament for the treatment, prevention or amelioration of a Flavivirus infection, such as those caused by YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) or MODV (Modoc virus) are provided. The antiviral compositions of the present invention are suitable for oral administration to a Flavivirus-infected subject or a subject at risk of a Flavivirus infection, such as a human or other mammal. | 2012-08-16 |
20120208779 | MACROLIDE SYNTHESIS PROCESS AND SOLID-STATE FORMS - Described are methods for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides. Also described are solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from) such crystalline forms, methods for making medicaments comprising (or derived from) such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms. | 2012-08-16 |
20120208780 | HYBRID NANOMATERIALS CONSISTING OF PSEUDOROTAXANES, PSEUDOPOLYROTAXANES, ROTAXANES, POLYROTAXANES, NANOPARTICLES AND QUANTUM DOTS - This invention provides the synthesis of biocompatible and high functional hybrid nanomaterials consisting of pseudorotaxanes, pseudopolyrotaxanes, rotaxanes, polyrotaxanes, nanoparticles and quantum dots (QDs). The molecular self-assembly of hybrid nanomaterials lead to the formation of nano-objects with different shapes such as core-shell, spindle-like or necklaces. Due to their well-defined molecular self-assemblies, carbohydrate backbone, high functionality and several types of functional groups together with the high luminescence yield, thermal and physical properties and synthesized hybrid nanostructures were recognized as promising candidates for a wide range of applications. | 2012-08-16 |
20120208781 | AMINOGLYCOSIDE DOSING REGIMENS - The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections. | 2012-08-16 |
20120208782 | Modulation of Growth of Bifidobacteria Using a Combination of Oligosaccharides Found in Human Milk - A prebiotic formulation for oral administration to a human comprising 2′-fucosyllactose, 3′-sialyllactose and 6′-sialyllactose, and a method for modulating or stimulating the growth of | 2012-08-16 |
20120208783 | Medicine, Food And Drink Or Feed Containing Sphingomyelin - It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk. | 2012-08-16 |
20120208784 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES - The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: | 2012-08-16 |
20120208785 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses - The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications. | 2012-08-16 |
20120208786 | BISPHOSPHONATE COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE - The present invention provides for methods and compositions for treating and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, functional analogue or a pharmaceutically effective salt thereof. | 2012-08-16 |
20120208787 | CRYSTALLINE FORM OF FOSAMPRENAVIR CALCIUM - The present invention relates to a crystalline form of fosamprenavir calcium. The crystalline form of the present invention is designated as Form II of fosamprenavir calcium. The present invention also relates to a process for the preparation of crystalline Form II of fosamprenavir calcium. The present invention further relates to a pharmaceutical composition comprising crystalline Form II of fosamprenavir calcium. The present invention relates further to a method of treating a HIV infection using crystalline Form II of fosamprenariv calium. | 2012-08-16 |
20120208788 | Tetracycline Compounds - The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use. | 2012-08-16 |
20120208789 | HYDROSWELLABLE, SEGMENTED, ALIPHATIC POLYURETHANES AND POLYURETHANE UREAS - Hydroswellable, absorbable and non-absorbable, aliphatic, segmented polyurethanes and polyurethane-urea capable of swelling in the biological environment with associated increase in volume of at least 3 percent have more than one type of segments, including those derived from polyethylene glycol and the molecular chains are structurally tailored to allow the use of corresponding formulations and medical devices as carriers for bioactive agents, rheological modifiers of cyanoacrylate-based tissue adhesives, as protective devices for repairing defective or diseased components of articulating joints and their cartilage, and scaffolds for cartilage tissue engineering. | 2012-08-16 |
20120208790 | ION CHANNEL MODULATORS AND METHODS OF USE - In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels. | 2012-08-16 |
20120208791 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES - The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. | 2012-08-16 |
20120208792 | PROTEIN KINASE MODULATORS - The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules. | 2012-08-16 |
20120208793 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR - Thieno- and furo-pyrimidine compounds are described, which are useful as H | 2012-08-16 |
20120208794 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF - The present invention provides a fused heterocycle derivative having a strong Smo inhibitory activity, and use thereof. | 2012-08-16 |
20120208795 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS - The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamopituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent. | 2012-08-16 |
20120208796 | HETEROCYCLIC DERIVATIVES - The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by nicotinic acetylcholine receptors, such as schizophrenia and Alzheimer's disease. | 2012-08-16 |
20120208797 | PYRIMIDONE DERIVATIVES - A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: | 2012-08-16 |
20120208798 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use - Tetrahydroquinoline compounds of formula (I) | 2012-08-16 |
20120208799 | COMPOUNDS - The present invention relates to compounds of formula (I) | 2012-08-16 |
20120208800 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases - The use of compounds in the treatment of autoimmune and inflammatory diseases or conditions, pharmaceutical compositions containing such compounds and to methods for identifying compounds for use in the treatment of such diseases or conditions. | 2012-08-16 |
20120208801 | Aminodiazepines as Toll-Like Receptor Modulators - Provided are compositions and methods useful for modulation signaling through the Toll-like receptor TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency. | 2012-08-16 |
20120208803 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula I | 2012-08-16 |
20120208804 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE - This invention relates to substituted 1,3-oxazin-2-one compounds of the Formula (I), (II), (IIA), (IIB), (IIC), (II D), (IIE), (III), (III A), (III B), (IV), (IV A), (IV B), (IV C), (IV D), (V), (V A), (V B), (VI), (VI A), (VI B), (VII), (VII A), (VII B), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell. | 2012-08-16 |
20120208805 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS - The invention relates to novel compounds of formula I | 2012-08-16 |
20120208806 | Hsp90 Inhibitors - The present application provides compounds useful in the inhibition of Hsp90, and hence in the treatment of disease. | 2012-08-16 |
20120208807 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS - This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration. Formula (I) | 2012-08-16 |
20120208808 | PYRAZOLOPYRIMIDINE DERIVATIVES - Compounds of the formula (I), in which X, R | 2012-08-16 |
20120208809 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to novel 9H-pyrrolo[2,3-b:5,4-c′]dipyridine azacarbolines of formula (I), where: Z2, Z3, and Z4 are CH, CRa, CRs, or N; R3 is H, Hal; CF3, CHF2; OH, alkoxy; NH2, NH (alkyl), N(alkyl)2; C(O)O alkyl; CONH(alkyl), CON(alkyl)2; C1-C10 alkyl; aryl; heteroaryl; R6 is heteroaryl; Ra is CONH2, CONH alkyl, CONH cycloalkyl; CONH heterocycloalkyl; CON(alkyl)2; CON(alkyl)(heterocycloalkyl); CONHN(alkyl)2; C(O)heterocycloalkyl; Rs is H; Hal, OH; O-alkyl(C1-C10); NH2; N(alkyl(C1-C10) or cycloalkyl(C3-C7))2; NHC(O)R3a; N(alkyl(C1-C10)C(O)R3a; NHS(O2)R3a; N(alkyl)(C1-C10)S(O2)R3a; CO2R3a; SR3a; S(O)R3a; S(O2)R3a; Ra and Rs optionally form a cycle; R3a is selected from among Hal, CF3, C1-C10 alkyl; C3-C7 cycloalkyl; C2-C6 alkenyl; C2-C6 alkynyl; OH; O-alkyl(C1-C10); (C3-C7); heterocycloalkyl (C3-C7); NH2; NH-(alkyl(C1-C10) or cycloalkyl(C3-C7)); N(alkyl(C1-C10) or cycloalkyl(C3-C7))2; NH-(alkyl(C1-C10) or heterocycloalkyl(C3-C7)); N(alkyl(C1-C10) or heterocycloalkyl(C3-C7))2, as well as to the isomers and salts of said substances of formula (I) and to the therapeutic use thereof for treating cancer. | 2012-08-16 |